Loading

Please wait...

Braftovi

Generic Name: encorafenib (EN koe RAF e nib)
Brand Names: Braftovi
Braftovi (encorafenib) and Mektovi (binimetinib) in combination are used to treat melanoma with a BRAFV600E or BRAFV600K mutation. Includes Braftovi side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Braftovi

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Braftovi (encorafenib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Braftovi is a prescription medicine used in combination with another medicine called binimetinib (Mektovi) to treat melanoma (skin cancer) in people who have a "BRAF" gene mutation. These medicines are for use in treating melanoma that cannot be treated with surgery or has spread to other parts of the body. Braftovi should not be used to treat people with wild-type BRAF melanoma. Your healthcare provider will perform a test to make sure that this medicine is right for you Learn more

Braftovi Side Effects

Braftovi Side Effects

Note: This document contains side effect information about encorafenib. Some of the dosage forms listed on this page may not apply to the brand name Braftovi.

For the Consumer

Applies to encorafenib: oral capsule

Along with its needed effects, encorafenib (the active ingredient contained in Braftovi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking encorafenib:

More common

  • Bleeding gums
  • bloating
  • chills
  • constipation
  • coughing up blood
  • darkened urine
  • difficulty in breathing or swallowing
  • dizziness
  • fast heartbeat
  • fever
  • headache
  • hives, itching, skin rash
  • hoarseness
  • increased menstrual flow or vaginal bleeding
  • indigestion
  • irritation
  • joint pain, stiffness, or swelling
  • loss of appetite
  • nausea
  • nosebleed
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • partial or slight paralysis of the face
  • prolonged bleeding from cuts
  • red or black, tarry stools
  • red or dark-brown urine
  • redness, swelling, or pain of the skin
  • scaling of the skin on the hands and feet
  • swelling of the eyelids, face, lips, hands, or feet
  • thickening of the skin
  • tightness in the chest
  • tingling of the hands and feet
  • ulceration of the skin
  • unusual tiredness or weakness
  • vomiting
  • yellow eyes or skin

Some side effects of encorafenib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Back pain
  • burning, numbness, tingling, or painful sensations
  • change in taste
  • difficulty in moving
  • dry skin
  • hair loss, thinning of hair
  • loss of taste
  • muscular pain, tenderness, wasting, or weakness
  • pain in the arms or legs
  • stomach pain
  • unsteadiness or awkwardness
  • weakness in the arms, hands, legs, or feet

For Healthcare Professionals

Applies to encorafenib: oral capsule

Hematologic

Very common (10% or more): Anemia (36%), hemorrhage (19%), leukopenia (13%), lymphopenia (13%), neutropenia (13%)

Hypersensitivity

Common (1% to 10%): Hypersensitivity

Musculoskeletal

Very common (10% or more): Arthralgia (46%), myopathy (23%), pain in extremity (11%)

Ocular

Common (1% to 10%): Uveitis (e.g., iritis, iridocyclitis)

Metabolic

Very common (10% or more): Increased alkaline phosphatase (35%), hyperglycemia (28%), hypermagnesemia (26%), hyponatremia (18%)

Hepatic

Very common (10% or more): Increased gamma glutamyl transferase (45%), increased ALT (29%), increased AST (27%)

Oncologic

Common (1% to 10%): New primary melanoma, cutaneous squamous cell carcinoma (cuSCC) including keratoacanthoma (KA), basal cell carcinoma

Other

Very common (10% or more): Pyrexia (30%)

Nervous system

Very common (10% or more): Fatigue (46%), headache (22%), dizziness (15%), peripheral neuropathy (12%), intracranial hemorrhage in the setting of new or progressive brain metastases (sometimes fatal)

Common (1% to 10%): Facial paresis

Renal

Very common (10% or more): Creatinine increased (93%)

Cardiovascular

Uncommon (0.1% to 1%): QTc interval prolongation

Dermatologic

Very common (10% or more): Rash (53%), hyperkeratosis (49%), alopecia (38%), dry skin (26%), pruritus (21%)

Common (1% to 10%): Panniculitis

Gastrointestinal

Very common (10% or more): Nausea (41%), vomiting (30%), abdominal pain (28%), constipation (22%)

Common (1% to 10%): GI hemorrhage (including rectal hemorrhage), hematochezia, hemorrhoidal hemorrhage, pancreatitis

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Braftovi